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Review Article

Detection of lymph node metastases in penile cancer
Jonathan B. Bloom1, Michael Stern2, Neel H. Patel2, Michael Zhang2, John L. Phillips2
1

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; 2Department of Urology, New York

Medical College, Valhalla, NY, USA
Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV)
Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final
approval of manuscript: All authors.
Correspondence to: Jonathan B. Bloom. 10 Center Dr., Room 1-5940W, Bethesda, MD 20892, USA. Email: jonathan.bloom@nih.gov.

Abstract: Penile cancer (PC) is a relatively rare malignancy in the United States (US) but a greater concern
in developing nations. Lymph node imaging remains critical to the staging and treatment of this disease
as metastases develop in a predictable, anatomic fashion. Early surgical intervention remains a mainstay in
treatment and imaging often aids in decision making. This review highlights the indications for imaging
in both low-stage and advanced disease. Furthermore, we discuss the benefits and limitations of currently
available imaging for staging of inguinal and pelvic lymph nodes in PC and novel modalities in development.
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Introduction
In the United States (US), penile cancer (PC) is a relatively
rare malignancy with an estimated incidence of 2,320 cases
in 2018 and nearly 400 deaths (1). Approximately 35–40%
of patients with PC will present with ≥ clinical T2 disease
(2,3). In developing countries, with large income disparities
and those with low rates of circumcision, the incidence
of PC is far greater (4). Rural India has three times the
incidence of the US, and in Brazil the rate of new PCs may
reach 8.3 per 100,000 men (5). When men with PC present
for treatment, accurate staging is critical for prognostic
and therapeutic information (6). Early identification and
surgical removal of inguinal lymph nodes (ILNs) may
increase survival in men with metastatic disease (7). On the
contrary, men with advanced and potentially unresectable
nodal disease may be better suited with neoadjuvant
chemotherapy or radiation therapy (8). When considering
disease spread to ILNs, the most important prognostic
factor is the stage and grade of the penile lesion (9,10).
Low-grade and stage (≤ pT1a) tumors have positive ILN
rates under 10% while high-grade (≥ pT1b) tumors may
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metastasize to inguinal nodes in up to 75% of cases (11).
Having these risk factors, along with palpable disease
in the inguinal region, should heighten the physician’s
clinical suspicion for lymphatic spread (9,10). An important
caveat is that an examination of the inguinal area is often
unreliable, especially in overweight individuals, resulting
in many false negatives and false positives (12,13). Because
of this, clinicians often rely on imaging modalities to better
stage patients prior to treatment (13,14).
Urologists must be aware of the extent of metastatic spread
as this is the most important factor predictive of survival (15).
Multiple studies have found average 5-year disease-free
survival rates of 85–100%, 79–89%, 17–60%, and 0–17% for
pN0, pN1, pN2, and pN3, respectively (Table 1) (6,12,16,17).
PC has a predictable pattern of metastatic spread: first
spreading to the sentinel lymph node (SLN) which is often
located within the superficial lymph nodes near the central
and superior aspects of the saphenofemoral junction (18,19).
Metastases to inferior and deeper inguinal nodes and then
pelvic nodes may occur later (18). This review will highlight
the indications and available imaging modalities for detecting
inguinal and pelvic nodal metastases in the setting of PC.
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Table 1 Definitions of pathological staging of inguinal lymph nodes for penile cancer (8)
Staging

Definition

Clinical stage
cNX

Regional lymph nodes cannot be assessed

cN0

No palpable or visibly enlarged inguinal lymph nodes

cN1

Palpable mobile unilateral inguinal lymph node

cN2

Palpable mobile ≥2 unilateral inguinal lymph nodes or bilateral inguinal lymph nodes

cN3

Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral

Pathologic stage
pNX

Lymph node metastasis cannot be established

pN0

No lymph node metastasis

pN1

≤2 unilateral inguinal metastases, no ENE

pN2

≥3 unilateral inguinal metastases or bilateral metastases

pN3

ENE of lymph node metastases or pelvic lymph node metastases

ENE, extranodal extension.

Indications for imaging
Inguinal imaging is not required for all men with PC.
The National Comprehensive Cancer Network (NCCN)
guidelines indicate imaging in two clinical situations prior
to treatment: in patients with intermediate or high-risk
PC (clinical stage ≥ T1b) or in all men with palpable ILNs
on physical exam (8). These guidelines suggest obtaining
either computed tomography (CT) or magnetic resonance
imaging (MRI), with contrast if possible, of the abdomen
and pelvis, as well as chest imaging (8). In men who have
undergone surgical inguinal lymphadenectomy for pN23 disease, surveillance imaging (CT or MRI) is indicated
every three months for the first year and then every 6
months thereafter. For patients with unresectable inguinal
disease who undergo chemotherapy or radiation therapy as
neoadjuvant or primary treatment, repeat CT or MRI of the
abdomen and pelvis along with lung imaging is indicated
after treatment. In such a clinical scenario, clinicians may
consider positron emission tomography (PET)/CT as this
modality may have superior diagnostic performance over
conventional cross-sectional imaging (8).
Conventional imaging
Conventional cross-sectional imaging, such as CT or MRI,
often relies on size criteria (e.g., >8–10 mm) to diagnose
metastatic spread to lymph nodes. However, based solely on
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size criteria, a significant number of cancerous nodes may
go undiagnosed while benign enlarged nodes may be falsely
positive (Figure 1) (20). PC is known to cause inflammatory
changes in local nodes explaining a notoriously high rate of
false positives findings (21).
Graafland et al. looked at their experience with CT
imaging to detect metastatic spread to inguinal and pelvic
lymph nodes using different radiologic criteria to identify
suspicious nodes. In patients with low risk for inguinal
nodal involvement, an 8 mm cut-off in the short axis of the
node provided the highest accuracy for predicting a positive
node with a sensitivity of 87% and specificity of 81% (22).
For patients at high risk of inguinal nodal disease, the
criteria with the highest accuracy (88%) was the presence of
an irregular nodal border which had an improved specificity
of 95% (22). For high-risk patients, a cut off of 8 mm or
greater in the short axis yielded a sensitivity of 95% but
at the expense of specificity at just 54%. This threshold
measurement, 8 mm, also provided high sensitivity
(100%) when ruling out ipsilateral pelvic nodal disease but
decreased with increasing lymph node diameters (22).
MRI is another cross-sectional imaging technique to
stage ILNs. Lucchesi et al. found 13 of 15 (86.7%) cases
of ILN involvement using MRI compared to physical
exam which identified just 7 of the 15 (46.7%) nodes (23).
MRI may not provide significant additional information
over CT scans for ILN imaging but MRI may provide
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Figure 1 CT scans demonstrating a false-positive and true-positive when staging ILN. A 32-year-old man with HgT2 penile cancer
invading into the glans with imaging demonstrating a 2.6 cm left inguinal node (arrow) (A) and 1.9 cm left external iliac node (arrow) (B)
all of which were benign after robotic-assisted node dissection. An 82-year-old man with HgT2 penile cancer with 2.2 cm left inguinal
node (arrow) (C) with irregular borders and 1.8 cm left external iliac node (arrow) (D). Inguinal lymph node dissection was performed with
pathology demonstrating metastatic disease with tumor necrosis and extranodal extension.

Figure 2 A 47-year-old male with penile cancer. Sagittal T2W MR
image shows a large heterogenous mass involving almost the entire
penis (red bracket).

additional information when staging the primary tumor
(Figure 2) (24). MR images of the primary penile tumor are
optimally obtained after intracorporeal injection (ICI) of
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10 µg of prostaglandin E1 with axial, sagittal and coronal
images then obtained (25). Gadolinium contrast may help
to identify lymph nodes but only T1- and T2-weighted
images are necessary to evaluate penile anatomy and tumor
extension (25). MRI of the penis shows the muscular
wall of the urethra, tunica albuginea, and Buck’s fascia to
all be hypointense on both T1 and T2 weighted images
while the corpora cavernosa and corpus spongiosum have
intermediate signal intensity on T1-weighted imaging
and high signal intensity on T2-weighted imaging (25).
Hanchanale et al. studied 100 patients with clinical T1–T3
PC using MRI after prostaglandin E1 ICI and found MRI
to have a sensitivity and specificity for tunica albuginea
invasion of 82.1% and 73.6%, respectively (26). The
sensitivity and specificity of urethral invasion was 62.5%
and 82.1% in this study (26).
A unique approach to MR imaging utilizes a novel
contrast agent, ultra-small superparamagnetic iron oxide
particles (USPIO) such as ferumoxtran-10 or commercially
available ferumoxytol. The former has a half-life of 25 hours
while the latter has shorter half-life of 14–15 hours and is
less prone to allergic reactions (20,27). Ferumoxtran-10
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Figure 3 An 84-year-old male with penile cancer. Axial T2*-weighted MR image shows an enlarged lymph node in the left inguinal region
(arrow) (A). Axial T2*-weighted MR image obtained 24 hours after intravenous injection of ferumoxytol shows persistently high signal
intensity within the left inguinal adenopathy (arrow) (B) which suggests metastatic involvement of penile cancer. Axial 18F-FDG-PET/CT
image shows tracer uptake within the left inguinal adenopathy which confirms presence of metastasis (arrow) (C).

nanoparticles are taken up within the penile lymphatics,
phagocytosed by resident macrophages, and results in nodal
accumulation of contrast (20). Metastatic nodes are often
lacking in macrophages and therefore accumulate less of
this nanoparticle (20). Nanoparticles within a benign lymph
node result in a decreased T2* (susceptibility weighted)
images along with bright T2 images. In contrast, malignant
nodes will have bright T2 and T2*-weighted images
(Figure 3) (20). This technology has been utilized for
multiple cancers and has been proven effective for PC as
well (28,29). Tabatabaei et al. studied ferumoxtran-10 in
seven men with stage T1b–T2 PC and found a sensitivity
of 100%, specificity of 97%, positive predictive value of
81.2%, and negative predictive value of 100% (29).
SLN biopsy
The original lymph drainage of the penis was described
in 1977 by Ramon Cabanas who performed 100
lymphangiograms (LAGs) in men with both benign and
malignant penile lesions (19). In such LAGs, the SLN was
mapped to the antero-medial border of the epigastricsaphenous junction which was therefore recommended to
be resected based on anatomical landmarks. Furthermore,
in 31 cases where SLN biopsy was negative, there was no
disease recurrences within 3- and 5-year overall survival
rate was 90% (19). Despite this promising data, additional
studies showed that the use of Cabanas’ anatomic landmarks
alone may yield false-negative findings due to altered
lymphatic drainage (30,31).
Due to the risk of false-negative results in SLN biopsies,
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physicians turned to other, real-time methods to identify
lymphatic drainage combining dynamic sentinel node biopsy
(DSNB) techniques used to diagnose other malignancies (32).
Isosulfan blue dye travels through the lymphatic channels
allowing surgeons to visualize channels intraoperatively
and had previously been used in malignant melanoma to
visualize the SLN (32). Furthermore, Krag et al. developed
a technique of using a gamma-ray detector after injection
of a radiolabeled technetium ( 99m Tc)-nanocolloid for
localization of the SLN in breast cancer (33). Horenblas
et al. first combined these procedures and performed LSG
on 55 patients with T2–T3 PC disease using both blue dye
and a radiolabeled 99mTc-nanocolloid (34). One day prior to
surgery, 99mTc-nanocolloid is injected near the tumor site
and immediate dynamic imaging was performed, followed
by static images at 30 minutes and 2 hours post injection
(Figure 4). These locations were marked on the patient’s
skin to plan for surgery the following day. Blue dye was then
injected in a similar manner immediately prior to surgery to
aid in intraoperative identification. In the initial series, only
one patient had tumor recurrence after negative DSNB. A
subsequent study of 250 more surgically explored groins
found that the false-negative rate decreased from 19.2% to
4.8% and the complication rate decreased from 10.2% to
5.7% as these practitioners gained experience (35).
DSNB is indicated in men with PC who are at
intermediate to high risk of having metastases to the ILNs
without palpable disease (6). This procedure should be
done bilaterally with the goal of preventing the morbidity
of bilateral ILN dissections (ILND). However, if the
DSNB is positive, a complete ILND should be performed.
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Figure 4 A 38-year-old man with HgT1 penile cancer who underwent wide local excision of primary lesion. Axial CT imaging (A)
demonstrates 2.8 cm right inguinal lymph node (arrow). 18F-FDG PET (B) image shows tracer uptake within the right inguinal adenopathy
(arrow) which confirms presence of metastasis. Lymphoscintigraphy was performed (C) showing sentinel node corresponding with nodal
mass (arrow). Inguinal lymph node dissection was performed with final pathology revealing 3.5 cm nodal metastasis and 9 benign lymph
nodes.

DSNB should only be performed at experienced centers to
minimize the chance of a false-negative node result.
The principle behind LSG was then merged with CT
technology to perform single-photon emission computed
tomography-CT (SPECT-CT). Leijte et al. performed both
standard DSNB while at the same time performing SPECTCT at 2 hours post-injection of 99mTc-nanocolloid (18).
Combining these techniques gave both the functional
information of the lymphatic drainage and the spatial
resolution of CT. The technique was performed in 86
clinically negative groins and with the combination of
both techniques, lymphatic drainage was demonstrated
in 95.3%. SNL was not detected in the zones inferior
to the saphenofemoral junction nor was there drainage
directly into the pelvis (18). Another study of this combined
technology showed SPECT/CT to have a high sensitivity
and specificity of 88.8% and 86.7%, respectively (36).
Another novel method of identifying the SLN and
patterns of drainage requires a fluorescent dye, indocyanine
green (ICG), which is injected near the primary lesion site
prior to inguinal lymphadenectomy (37,38). Markuszewski
et al. compared ICG to 99mTc-nanocolloid radiotracer which
was injected with ICG prior to surgery and then used a
gamma-ray detector and near infrared fluorescence (NIRF)
camera to detect these compounds, respectively (38).
Both methods of SLN biopsy were able to detect SLNs
intraoperatively, including those with metastases (38).
Robotic-assisted inguinal lymphadenectomy with a NIRF
camera may become a more standardized approach in
performing this procedure with comparable node yields
and lower morbidity. ICG may become a more commonly
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utilized method of intraoperative identification of lymph
nodes during such procedures (37,39). Furthermore,
ICG and 99mTc-nanocolloid can be combined into one
compound for hybrid approaches to first guide the surgeon
via radiotracer mapping and then further intraoperative
visualization with ICG (40).
Ultrasound (US) has also been used to assess inguinal
nodes during the time of surgery. Kroon et al. performed
fine-needle aspiration cytology (FNAC) prior to DSNB or
inguinal node dissection in 83 clinically negative groins and
found US with FNAC to have a sensitivity and specificity
of 39% and 100%, respectively (41). Intraoperative US has
also been applied to palpable nodal disease during DSNB
to identify more metastatic nodes that were missed during
DSNB possibly due to lymphatic channel blockage (42).
Contrast-enhanced ultrasonography (CEUS) is another
novel technique that has been used in other malignancies
for sentinel node mapping but has yet to see use with PC.
For example, breast cancer often utilizes a SLN biopsy
and this technique was studied in 54 patients and found
to have a sensitivity of 89% with all five cancerous nodes
detected (43). Another example supports this concept when
applied to ILNs. Lahtinen et al. found the sensitivity of
the procedure to be 81.2% in identifying SLN from vulvar
cancer, enabling complete resection intraoperatively (44).
Another modality to evaluate metastatic lymph nodes
in PC is PET imaging utilizing 18F-fluorodeoxyglucose
(18F-FDG) which is taken up by malignant cells more
rapidly (45). This functional imaging is then combined with
the anatomic information obtained from CT (Figure 4).
Souillac et al. compared the accuracy of 18F-FDG-PET/
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CT in both patients with clinically positive and clinically
negative inguinal node exams (46). 18F-FDG-PET/CT
was found to have a sensitivity of 75% and specificity of
87.5% in clinically negative patients while the sensitivity
was 37.5% and 97.2% in patients with clinically positive
nodes (46). This low sensitivity highlights the importance to
incorporate clinical suspicion, based on physical exam and
tumor stage, into decision making. A meta-analysis of seven
total studies showed an overall sensitivity of 80.9% and
specificity of 92.4% for detection of lymph nodes. However,
sensitivity varied based on clinical exam with an increase in
sensitivity to 96.4% in clinically positive exams, decreasing
to 56.5% in patients with negative exams (47).
18F-FDG-PET/CT has additional value in predicting
the nodal status outside of the groin. Graafland et al.
evaluated 18 patients with metastatic spread to inguinal
nodes and then underwent evaluation of their pelvic nodes
and found a sensitivity of 91% and specificity of 100% (48).
Another study of patients with advanced disease, all
of whom had inguinal disease and 21/48 (43.8%) who
presented with distant metastases found 18F-FDG-PET/
CT to have a sensitivity and specificity of 82% and 93%,
and overall was able to detect 33% more metastatic lesions
than cross-sectional imaging alone (49).

Footnote

Conclusions

7.

Accurate staging of ILNs is important to administer the
multiple modalities required in the treatment of PC and
in the proper sequence. Conventional cross-sectional
imaging such as CT and MRI rely mainly on size criteria
to determine benign vs. malignant lymph nodes and may
yield to false-negatives and positives. MRI may contribute
an additional role in staging of the primary tumor. DSNB
performed with radiotracers and dyes incorporates
functional information and may yield false-negative rates
as low as 5%. 18F-FDG-PET imaging is indicated in
advanced disease and has high specificity and sensitivity
which increases with stage. Many imaging and surgical
methods are available to identify suspicious nodes but
physicians’ clinical suspicion, based on the primary tumor
grade and stage, should weigh heavily on management
decisions.
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